 CAMBRIDGE, Mass., Jan. 11, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will participate in the upcoming H.C. Wainwright Bioconnect 2021 Conference, which will take place January 1114. 